4NE1 Stock Overview
Engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Accolade, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.38 |
| 52 Week High | US$13.60 |
| 52 Week Low | US$2.82 |
| Beta | 2.07 |
| 1 Month Change | -3.98% |
| 3 Month Change | -1.17% |
| 1 Year Change | -70.61% |
| 3 Year Change | -85.43% |
| 5 Year Change | n/a |
| Change since IPO | -90.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4NE1 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.4% | 0.7% | 0.6% |
| 1Y | -70.6% | 18.0% | 7.2% |
Return vs Industry: 4NE1 underperformed the German Healthcare industry which returned 18% over the past year.
Return vs Market: 4NE1 underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 4NE1 volatility | |
|---|---|
| 4NE1 Average Weekly Movement | 6.9% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4NE1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4NE1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,400 | Raj Singh | www.accolade.com |
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions.
Accolade, Inc. Fundamentals Summary
| 4NE1 fundamental statistics | |
|---|---|
| Market cap | €273.44m |
| Earnings (TTM) | -€76.82m |
| Revenue (TTM) | €422.99m |
0.6x
P/S Ratio-3.6x
P/E RatioIs 4NE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4NE1 income statement (TTM) | |
|---|---|
| Revenue | US$441.03m |
| Cost of Revenue | US$228.29m |
| Gross Profit | US$212.74m |
| Other Expenses | US$292.84m |
| Earnings | -US$80.10m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
Jan 09, 2025
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 48.24% |
| Net Profit Margin | -18.16% |
| Debt/Equity Ratio | 49.4% |
How did 4NE1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 19:39 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/02/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Accolade, Inc. is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Zhilin Long | Berenberg |
| Allen Lutz | BofA Global Research |